Sitagliptin versus placebo in the treatment of nonalcoholic fatty liver disease: A randomized controlled trial

BACKGROUND & AIMS: Uncontrolled studies show sitagliptin, an oral DPP-4 inhibitor, may improve alanine aminotransferase (ALT) and liver histology in nonalcoholic fatty liver disease (NAFLD) patients. We aimed to compare sitagliptin versus placebo's efficacy in reducing liver fat measured by...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Hepatol
Hoofdauteurs: Cui, Jeffrey, Philo, Len, Nguyen, Phirum, Hofflich, Heather, Hernandez, Carolyn, Bettencourt, Ricki, Richards, Lisa, Salotti, Joanie, Bhatt, Archana, Hooker, Jonathan, Haufe, William, Hooker, Catherine, Brenner, David A, Sirlin, Claude B, Loomba, Rohit
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2016
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5081213/
https://ncbi.nlm.nih.gov/pubmed/27151177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2016.04.021
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items